Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Activity of SAR422459 in Stargardt’s Macular Degeneration
2024-513501-31-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Aug 2024
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of SAR422459 in Fundus Flavimaculatus (FF), sponsored by Sanofi. Primary endpoint: Incidence of adverse events. Planned start Aug 2024; status: authorised.
02
Drugs
SAR422459
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2024-513501-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513501-31-00.